- Home
- CLBT vs LNTH Comparison
CLBT vs LNTH Comparison
Compare CLBT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLBT | LNTH |
|---|---|---|
| Founded | 1999 | 1956 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CLBT | LNTH |
|---|---|---|
| Price | $17.17 | $64.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $24.40 | ★ $78.00 |
| AVG Volume (30 Days) | 788.3K | ★ 936.2K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.31 | ★ 2.39 |
| Revenue | $455,903,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $20.25 | $0.01 |
| Revenue Next Year | $17.24 | $0.26 |
| P/E Ratio | $54.32 | ★ $26.85 |
| Revenue Growth | ★ 18.36 | 1.95 |
| 52 Week Low | $13.10 | $47.25 |
| 52 Week High | $26.30 | $111.29 |
Technical Indicators
Market Signals| Indicator | CLBT | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 46.49 |
| Support Level | $17.78 | $64.34 |
| Resistance Level | $18.80 | $70.33 |
| Average True Range (ATR) | 0.51 | 1.70 |
| MACD | -0.15 | -0.72 |
| Stochastic Oscillator | 6.03 | 8.20 |
Price Performance
Historical ComparisonAbout CLBT Cellebrite DI Ltd.
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.